Opendata, web and dolomites

LuMaSense

A Non-Invasive Test for Guiding Follow–up of Patients with CT-Detected Lung Nodules

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LuMaSense project word cloud

Explore the words cloud of the LuMaSense project. It provides you a very rough idea of what is the project "LuMaSense" about.

marketable    unnecessary    off    breath    alone    reduce    healthcare    positive    save    plans    group    speed    billion    diag    evaluation    delay    health    rate    poc    24    combination    portability    12    false    completing    usefulness    utilizing    transfer    malignant    transform    96    ip    powerful    prototype    patients    operation    competitors    auxiliary    device    sensitivity    erc    16    undergone    commercially    lc    mature    relies    fund    countries    urgent    grant    oriented    placement    technique    ct    immediately    morbidity    detected    programs    distinguish    successful    nodule    action    specificity    covered    company    market    costly    exists    spin    cancer    tool    treatment    optimal    clinical    stand    complexity    lung    portfolio    optimization    front    ldct    cancerous    economic    care    complementary    rationale    conducting    noninvasive    worldwide    implication    idea    stages    mortality    screening    technological    translated    invasive   

Project "LuMaSense" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 150˙000.00

Map

 Project objective

This PoC is a commercially-oriented spin-off from our “DIAG-CANCER” ERC project, addressing an urgent clinical need in the field of lung cancer (LC). The rationale behind this PoC is that CT-based LC screening programs are emerging in many countries worldwide. However, the high false positive rate of this technique (96% out of the 24% positive CT findings are non-cancerous) has been a major challenge in front those plans. This is because the CT-detected non-cancerous group has undergone unnecessary invasive procedures that are both costly and associated with significant morbidity and mortality. With this PoC project, we aim to increase the specificity of the LDCT based screening program by utilizing an auxiliary noninvasive breath test to distinguish between malignant and non-cancerous CT findings. The proposed breath test relies on a novel stand-alone device that provide an improved combination of speed, sensitivity, portability, low complexity, easy operation and low production cost. In order to transform our idea and current technology into a marketable device we propose taking several steps: (i) optimization of a prototype device and evaluation of its clinical usefulness through clinical studies; (ii) completing the IP portfolio of the device; and (iii) conducting detailed market research to identify the optimal placement in the healthcare market and possible competitors. After completing these stages, to be covered by the present grant, we propose to proceed to the technology transfer to a mature health care company or through complementary fund to advance the technological plans. If successful, the proposed PoC can be translated immediately into a powerful tool for the management of nodule-positive patients. It will both reduce the rate of unnecessary invasive procedures, and on the other hand, will avoid treatment delay when cancer exists. The economic implication of this action is a significant save of ~$12-16 billion for the healthcare system worldwide.

 Publications

year authors and title journal last update
List of publications.
2016 Inbar Nardi-Agmon, Manal Abud-Hawa, Ori Liran, Naomi Gai-Mor, Maya Ilouze, Amir Onn, Jair Bar, Dekel Shlomi, Hossam Haick, Nir Peled
Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer
published pages: 827-837, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.02.017
Journal of Thoracic Oncology 11/6 2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMASENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMASENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

FunDiT (2019)

Functional Diversity of T cells

Read More